ReviewFungal biology and biotechnology2022
Exploring fungal RiPPs from the perspective of chemical ecology.
Review in Fungal biology and biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Comparative Whole-Genome Sequence Analysis ofJournal of fungi (Basel, Switzerland) · 2026Article
- The "dark magic mushroom" co-produces amatoxins and psilocybin.bioRxiv : the preprint server for biology · 2026Article
- Ustiloxins as Emerging Contaminants in Rice Agroecosystems: Environmental Occurrence, Ecotoxicological Impacts, and Risk Implications-A Complete Review.Journal of basic microbiology · 2026Review
- Leaderless RiPPs expand the repertoire of fungal secondary metabolites.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- RadicalJournal of the American Chemical Society · 2026Article
- A class of benzofuranoindoline-bearing heptacyclic fungal RiPPs with anticancer activities.Nature chemical biology · 2025Article
- Whole-genome sequencing and comparative genomic analysis ofMicrobial genomics · 2025Article
- Bioinformatic exploration of RiPP biosynthetic gene clusters in lichens.Fungal biology and biotechnology · 2025Article
- Screening of Microorganisms Isolated from Stingless Bees' Larval Food in the Biocontrol ofJournal of nematology · 2025Article
- Fungal Metabolomics: A Comprehensive Approach to Understanding Pathogenesis in Humans and Identifying Potential Therapeutics.Journal of fungi (Basel, Switzerland) · 2025Review
- Bacterial Cytochrome P450 Catalyzed Macrocyclization of Ribosomal Peptides.ACS bio & med chem Au · 2024Review
- Comparative analysis of the genomes and aflatoxin production patterns of three species within the Aspergillus section Flavi reveals an undescribed chemotype and habitat-specific genetic traits.Communications biology · 2024Article
- De Novo Genome Assembly ofGenes · 2024Article
- The Metabolic Potential of the Human Lung Microbiome.Microorganisms · 2024Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Since the initial detection, in 2007, of fungal ribosomally synthesised and post-translationally modified peptides (RiPPs), this group of natural products has undergone rapid expansion, with four separate classes now recognised: amatoxins/phallotoxins, borosins, dikaritins, and epichloëcyclins. Largely due to their historically anthropocentric employment in medicine and agriculture, novel fungal proteins and peptides are seldom investigated in relation to the fungus itself. Therefore, although the benefits these compounds confer to humans are often realised, their evolutionary advantage to the fungus, the reason for their continued production, is often obscure or ignored. This review sets out to summarise current knowledge on how these small peptide-derived products influence their producing species and surrounding biotic environment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.